Phase I/II, Multi-center, Open Label, Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti Tumor Activity of ASP9521 in Patients With Metastatic Castrate-resistant Prostate Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs ASP 9521 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Astellas Pharma
- 10 Jun 2017 Biomarkers information updated
- 10 Jun 2014 Last checked against ClinicalTrials.gov record
- 01 Sep 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.